Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: Preclinical in vitro/in vivo studies

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 955-961

  Caserini, Claudia ^a   Pratesi, Graziella ^a   Tortoreto, Monica ^a   Bedogné, Barbara ^a   Carenini, Nives ^a   Supino, Rosanna ^a   Perego, Paola ^a   Righetti, Sabina C ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN P53; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; CLONE CELLS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; GENES, P53; HUMANS; MICE; MICE, NUDE; MUTATION; OVARIAN NEOPLASMS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030948772     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
2. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
3. Giovanella, B. C., Hinz, H. R., Kozielski, A. J., Stehlin, J. S., Silber, R., and Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res., 51: 3052-3055, 1991.
4. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
5. Carmichael, J., Gordon, A., Malfetano, J., Gore, M., Spaczynski, M., Davidson, N., Savage, J., Clarke-Pearson, D., Hudson, I., Broom, C., and Ten Bokkel Huinink, W. Topotecan, a new active drug, vs paclitaxel in advanced epithelial ovarian carcinoma: international topotecan study group trial. Proc. Am. Soc. Clin. Oncol., 15: 283, 1996.
6. Kudelka, A. P., Tresukosol, D., Edwards, C. L., Freedman, R. S., Levenback, C., Chantarawiroj, P., Gonzalez de Leon, C., Kim, E. E., Madden, T., Wallin, B., Hord, M., Verschraegen, C., Raber, M., and Kavanagh, J. J. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol., 14: 1552-1557, 1996.
7. Pratesi, G., Tortoreto, M., Corti C., Giardini R., and Zunino, F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br. J. Cancer, 71: 525-528, 1995.
8. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
9. Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
10. Sheng Wu, G., and El-Deiry, W. S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin. Cancer Res., 2: 623-633, 1996.
11. Nelson, W. G., and Kastan, M. B. DNA strand-breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
12. Oren, M. Relationship of p53 to the control of apoptotic cell death. Cancer Biol., 5: 221-227, 1994.
13. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
14. Righetti, S. C., Della Torre, G., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C., Cornarotti, M., Oriana, S., Bohm, S., Bresciani, G. L., Spatti, G. B., and Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res., 56: 689-693, 1996.
15. Bénard, J., Da Silva, J., De Blois, M. C., Boyer, P., Duvillard, P., Chiric, E., and Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROV-1, in tissue culture and in nude mice. Cancer Res., 45: 4970-4979, 1985.
16. Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Premkumar Reddy, E., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., Westin, E. H., Wong-Staal, F., Gallo, R. C., and Aaronson, S. A. Cellular genes analogues to retroviral onc genes are transcribed in human tumour cells. Nature (Lond.), 295: 116-119, 1982.
17. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. M., and Abbott B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3: 1-88, 1972.
18. Pratesi, G., Dal Bo, L., Paolicchi, A., Tonarelli, P., Tongiani, R., and Zunino, F. The role of the glutathione-dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts. Ann. Oncol., 6: 283-289, 1995.
19. Tietze, F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal. Biochem., 27: 502-522, 1969.
20. Habig, W. H., Pabst, M. J., and Jacoby, W. B. Glutathione-S-transferase: the first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249: 7130-7139, 1974.
21. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., and Pierotti, M. A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91: 1753-1760, 1993.
22. Scheffner, M., Munger, K., Byrne, J. C., and Howley, P. M. The state of p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
23. Mattern, M. R., Hofmann, G. A., McCabe, F. L., and Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res., 51: 5813-5816, 1991.
24. Marchesini, R., Colombo, A., Caserini, C., Perego, P., Supino, R., Capranico, G., Tronconi, M., and Zunino, F. Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int. J. Cancer, 66: 342-346, 1996.
25. Kotoh, S., Naito, S., Yokomizo, A., Kumazawa, J., Asakuno, K., Kohno, K., and Kuwano, M. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res., 54: 3248-3252, 1994.
26. Goldwasser, F., Valenti, M., Torres, R., Kohn, K. W., and Pommier, Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res., 2: 687-693, 1996.
27. Underberg, W. J. M., Goossen, R. M. J., Smith, B. R., and Beijnen, J. H. Equilibrium kinetics of the new experimental antitumour compound SK&F 104864-A in aqueous solution. J. Pharm. Biomed. Anal., 8: 681-683, 1990.
28. Dubrez, L., Goldwasser, F., Genne, P., Pommier, Y., and Solary, E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (Baltimore), 9: 1013-1024, 1995.